Skin health products innovator SkinBioTherapeutics says revenue growth is on the cards for 2026 as its products hit high street shelves.
The Newcastle-based firm published results for the year to the end of June, showing a boost in revenue from £1.2m to £4.6m and a narrowing of operating losses from £2.9m to £1.1m. Bosses said the boosted sales reflected continued success of its AxisBiotix-Ps product and a full year trading of the Dermatonics, which it acquired last year.
In June, SkinBioTherapeutics signed a contract with health and beauty retailing giant Superdrug to sell its AxisBiotix- Ac food supplement which targets irritation prone skin and blemish prone skin. The products were initially rolled out to about 180 shops around the country, and will be phased into the rest of Superdrug's sites starting from Spring 2026.
The work - which has included a significant effort to meet stringent launch deadlines - has given bosses confidence of further growth in 2026. And with the acquisition of Bio-Tech Solutions Ltd (BTS) in October and a share placing having boosted cash to £4.8m from £800,000, the firm has also hinted at the potential for new acquisitions.
The Cambridgeshire-based Dermatonics business - which makes a range of products including heal balm, treatment for warts and verrucas and dry skin relief - saw revenue grow from £1m to £2.2m. Ebitda increased from £100,000 to £500,000.
Meanwhile, BTS generated revenues of £1.4m and Ebitda of £100,000. The performance of both SkinBioTherapeutics-owned companies was slightly below expectations owing, bosses said, to the timing of orders.
Stuart Ashman, CEO of SkinBioTherapeutics said: "FY25 has been an important year of further evolution for the group. We strengthened our commercial relationship with Croda, culminating in the global industry launch of SkinBiotix under the brand name, Zenakin. We also saw material financial contributions and synergies from new acquisitions, Dermatonics and Bio-Tech Solutions.
"We finished the year with the signing of an exclusive commercial deal with one of the leading º£½ÇÊÓƵ High Street retailers, Superdrug Stores plc, which resulted in two lines of AxisBiotix being stocked in select stores nationwide post year end.
“Achieving these milestones, especially the partnership agreements and acquisitions, can take time to land, and the benefit from these can also take time to flow through at the group level. However, we are now seeing royalty inflow and we have two lines of AxisBiotix products on High Street Stores shelves. We anticipate the cumulative benefits of these partnerships will become more visible in our accounts as product numbers and sales increase over time.
“We have seen a great start to FY26 and anticipate another year of growth from direct and indirect sales. We are especially looking forward to seeing a new generation of cosmetics products with Zenakine included and further high street exposure for AxisBiotix as the Superdrug nationwide roll-out continues."
